Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting
20604 studies found for:    T
Show Display Options
Rank Status Study
1 Recruiting CAR-T Cell Immunotherapy for EphA2 Positive Malignant Glioma Patients
Conditions: EphA2 Positive Malignant Glioma;   CAR-T Cell Immunotherapy
Intervention: Biological: CAR-T cell immunotherapy
2 Terminated A Phase 0, Open Label, Multi-Center, Exploratory and Safety Study of [F-18]T808
Condition: Alzheimers Disease
Intervention: Radiation: [F18] T808
3 Not yet recruiting CAR-T Hepatic Artery Infusions for CEA-Expressing Liver Metastases
Condition: Liver Metastases
Intervention: Biological: anti-CEA CAR-T cells
4 Recruiting Preventative/Preemptive Adoptive Transfer of Peptide Stimulated CMV/EBV Specific T-cells in Patients After Allogeneic Stem Cell Transplantation
Condition: Patients Undergoing Allogeneic Stem Cell Transplantation
Intervention: Biological: CMV/EBV specific T-cell
5 Recruiting CAR-T Hepatic Artery Infusions and Sir-Spheres for Liver Metastases
Condition: Liver Metastases
Interventions: Biological: anti-CEA CAR-T cells;   Device: Sir-Spheres
6 Recruiting CAR-T Cell Immunotherapy for HCC Targeting GPC3
Conditions: GPC3 Positive Hepatocellular Carcinoma;   CAR-T Cell Immunotherapy
Intervention: Biological: CAR-T cell immunotherapy
7 Completed
Has Results
Can Oral T3 Normalize Thyroid Hormone Levels Following Cardiopulmonary Bypass in Children?
Condition: Low T3 Syndrome
Interventions: Drug: Oral T3 Low dose;   Drug: Placebo;   Drug: Oral T3 high dose
8 Completed CEA-Expressing Liver Metastases Safety Study of Intrahepatic Infusions of Anti-CEA Designer T Cells
Condition: Liver Metastases
Intervention: Biological: anti-CEA 2nd generation designer T cells
9 Recruiting Trial of Immune Reconstitution With Activated T-Cells Following Lymphodepleting Chemotherapy in Patients With Chronic Lymphocytic Leukemia (CLL)
Conditions: Leukemia;   Chronic Lymphocytic Leukemia
Interventions: Drug: Rituximab;   Drug: Cyclophosphamide;   Drug: Fludarabine monophosphate;   Drug: Bendamustine;   Biological: Activated T-Cell Infusion;   Drug: Lenalidomide;   Behavioral: Phone Calls
10 Not yet recruiting Multi-Dose CD30 CAR T Cells, Relapsed CD30 Expressing Lymphoma (RELY-30)
Conditions: Hodgkin's Lymphoma;   Non-Hodgkin Lymphoma
Interventions: Genetic: CAR T Cells;   Drug: Cyclophosphamide;   Drug: Fludarabine
11 Recruiting Memory Enriched T Cells Following Stem Cell Transplant in Treating Patients With Recurrent B-Cell Non-Hodgkin Lymphoma
Conditions: Recurrent Diffuse Large B-Cell Lymphoma;   Recurrent Mantle Cell Lymphoma;   Refractory Diffuse Large B-Cell Lymphoma;   Refractory Mantle Cell Lymphoma;   Transformed Recurrent Non-Hodgkin Lymphoma
Interventions: Biological: Autologous CD19CAR-CD28-CD3zeta-EGFRt-expressing Tcm-enriched T cells;   Biological: Autologous CD19CAR-CD28-CD3zeta-EGFRt-expressing Tn/mem-enriched T-lymphocytes;   Other: Laboratory Biomarker Analysis
12 Recruiting Ph 2 Study of Sipuleucel-T W/ or W/O Radium-223 in Men With Asymptomatic or Minimally Symptomatic Bone-MCRPC
Condition: Prostate Cancer
Interventions: Drug: Radium-223;   Biological: Sipuleucel-T
13 Recruiting Trial of Adoptive T Cell Therapy With Activated P53 Specific T Cells for Treatment of Advanced Colorectal Cancer
Condition: Colorectal Carcinoma
Intervention: Biological: re-activated T cells
14 Completed Assessment of the Clinical Efficacy and Acceptability of Think Positive (T+) in Diabetes Management
Condition: Diabetes (Insulin-requiring, Type 1 or Type 2)
Intervention: Device: Mobile phone telehealth application: Think Positive (T+)
15 Recruiting Evaluation of CAR19 T-cells as an Optimal Bridge to Allogeneic Transplantation
Condition: Diffuse Large B-Cell Lymphoma
Interventions: Procedure: Leukapheresis;   Drug: Cyclophosphamide;   Drug: Fludarabine;   Biological: CAR19 T-Cells
16 Terminated Trial of Second Generation Designer T Cells in Colorectal Carcinoma
Condition: Colorectal Cancer
Intervention: Biological: Gene Modified T Cells
17 Not yet recruiting T Cell Immunotherapy Plus Anti-PD1 Antibody in Advanced Solid Malignancies
Condition: Gastrointestinal Cancer Metastatic
Interventions: Drug: Standard Chemotherapy;   Drug: Cyclophosphamide;   Biological: Adoptive T Cell Infusion;   Drug: IL-2;   Drug: Pembrolizumab;   Behavioral: Phone Calls
18 Completed
Has Results
Study of the Booster Effect of DTaP-IPV-Hep B-PRP~T Combined Vaccine or Infanrix Hexa™ and Prevenar™ in Healthy Infants
Conditions: Diphtheria;   Tetanus;   Whooping Cough;   Hepatitis B;   Poliomyelitis
Interventions: Biological: DTaP-IPV-Hep B-PRP~T combined vaccine + Pneumococcal polysaccharide;   Biological: DTaP-Hep B-IPV // Hib Vaccine + Pneumococcal polysaccharide;   Biological: DTaP-IPV-Hep B-PRP~T + Pneumococcal polysaccharide vaccine
19 Completed
Has Results
Sipuleucel-T as Neoadjuvant Treatment in Prostate Cancer
Condition: Prostate Cancer
Interventions: Biological: Sipuleucel-T with Booster;   Biological: Sipuleucel-T without Booster
20 Completed Home-based Program "T&E" for Fall Prevention and QoL in Elderly: a Randomised Control Pilot-study
Condition: Accidental Falls
Interventions: Other: T&E;   Other: OTAGO

   Previous Page Studies Shown (1-20) Next Page (21-40) Show next page of results    Last Page
Indicates status has not been verified in more than two years